These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

380 related articles for article (PubMed ID: 23558214)

  • 41. Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration.
    Avery RL; Pieramici DJ; Rabena MD; Castellarin AA; Nasir MA; Giust MJ
    Ophthalmology; 2006 Mar; 113(3):363-372.e5. PubMed ID: 16458968
    [TBL] [Abstract][Full Text] [Related]  

  • 42. EFFECT OF RANIBIZUMAB AND AFLIBERCEPT ON RETINAL PIGMENT EPITHELIAL DETACHEMENT, SUBRETINAL AND INTRARETINAL FLUID IN AGE-RELATED MACULAR DEGENERATION.
    Sumarová P; Ovesná P; Matušková V; Beránek J; Michalec M; Michalcová L; Autrata D; Vysloužilová D; Chrapek O
    Cesk Slov Oftalmol; 2022; 78(4):176-185. PubMed ID: 35922146
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intraocular pressure in patients with neovascular age-related macular degeneration switched to aflibercept injection after previous anti-vascular endothelial growth factor treatments.
    Rusu IM; Deobhakta A; Yoon D; Lee M; Slakter JS; Klancnik JM; Thompson D; Freund KB
    Retina; 2014 Nov; 34(11):2161-6. PubMed ID: 25072648
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety and complications of intravitreal injections performed in an Asian population in Singapore.
    Xu Y; Tan CS
    Int Ophthalmol; 2017 Apr; 37(2):325-332. PubMed ID: 27236451
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Morphology and Visual Acuity in Aflibercept and Ranibizumab Therapy for Neovascular Age-Related Macular Degeneration in the VIEW Trials.
    Waldstein SM; Simader C; Staurenghi G; Chong NV; Mitchell P; Jaffe GJ; Lu C; Katz TA; Schmidt-Erfurth U
    Ophthalmology; 2016 Jul; 123(7):1521-9. PubMed ID: 27157149
    [TBL] [Abstract][Full Text] [Related]  

  • 46. PIGMENT EPITHELIAL DETACHMENT RESPONSE TO AFLIBERCEPT IN NEOVASCULAR AGE-RELATED MACULAR DEGENERATION REFRACTORY TO RANIBIZUMAB: Time Course and Drug Effects.
    de Massougnes S; Dirani A; Ambresin A; Decugis D; Marchionno L; Mantel I
    Retina; 2016 May; 36(5):881-8. PubMed ID: 27115852
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Clinical experience of switching anti-VEGF therapy from ranibizumab to aflibercept in age-related choroidal neovascularization.
    Van Lancker L; Petrarca R; Moutsouris K; Masaoutis P; Kampougeris G
    Eur J Ophthalmol; 2017 May; 27(3):342-345. PubMed ID: 27739561
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of ranibizumab on serous and vascular pigment epithelial detachments associated with exudative age-related macular degeneration.
    Panos GD; Gatzioufas Z; Petropoulos IK; Dardabounis D; Thumann G; Hafezi F
    Drug Des Devel Ther; 2013; 7():565-9. PubMed ID: 23874084
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Systemic counterregulatory response of placental growth factor levels to intravitreal aflibercept therapy.
    Zehetner C; Bechrakis NE; Stattin M; Kirchmair R; Ulmer H; Kralinger MT; Kieselbach GF
    Invest Ophthalmol Vis Sci; 2015 May; 56(5):3279-86. PubMed ID: 26024110
    [TBL] [Abstract][Full Text] [Related]  

  • 50. QUANTITATIVE ANALYSIS OF PIGMENT EPITHELIAL DETACHMENT RESPONSE TO DIFFERENT ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN WET AGE-RELATED MACULAR DEGENERATION.
    Balaskas K; Karampelas M; Horani M; Hotu O; Keane P; Aslam T
    Retina; 2017 Jul; 37(7):1297-1304. PubMed ID: 27755376
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Intravitreal aflibercept in high retinal pigment epithelial detachments].
    Boriskina LN; Khzardzhan YY; Zotov AS; Balalin AS; Kuznetsova NV
    Vestn Oftalmol; 2018; 134(5):92-98. PubMed ID: 30499545
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Retinal and Choroidal Changes after Anti Vascular Endothelial Growth Factor Therapy for Neovascular Age-related Macular Degeneration.
    Kim SW; Woo JE; Yoon YS; Lee S; Woo JM; Min JK
    Curr Pharm Des; 2019; 25(2):184-189. PubMed ID: 30892159
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bevacizumab simultaneous combined with dexamethasone implant for treatment of neovascular serous retinal pigment epithelial detachment secondary to neovascular age-related macular degeneration.
    Limon U; Sezgin Akcay BI
    Eur J Ophthalmol; 2022 Sep; 32(5):NP32-NP36. PubMed ID: 33781113
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Intravitreal bevacizumab combined with photodynamic therapy for the treatment of occult choroidal neovascularization associated with serous pigment epithelium detachment in age-related macular degeneration.
    Ladas ID; Kotsolis AI; Papakostas TD; Rouvas AA; Karagiannis DA; Vergados I
    Retina; 2007 Sep; 27(7):891-6. PubMed ID: 17891013
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Intravitreal ranibizumab and bevacizumab therapy for choroidal neovascularization in age-related macular degeneration with extensive pre-existing geographic atrophy.
    Amaro MH; Roller AB
    Arq Bras Oftalmol; 2012; 75(4):273-6. PubMed ID: 23258660
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Rescue therapy with intravitreal aflibercept for choroidal neovascularization secondary to choroidal osteoma non-responder to intravitreal bevacizumab and ranibizumab.
    Saitta A; Nicolai M; Neri P; Reibaldi M; Giovannini A; Mariotti C
    Int Ophthalmol; 2015 Jun; 35(3):441-4. PubMed ID: 25761547
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Short-term outcomes of aflibercept for neovascular age-related macular degeneration in eyes previously treated with other vascular endothelial growth factor inhibitors.
    Ho VY; Yeh S; Olsen TW; Bergstrom CS; Yan J; Cribbs BE; Hubbard GB
    Am J Ophthalmol; 2013 Jul; 156(1):23-28.e2. PubMed ID: 23664153
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Beneficial switch from aflibercept to ranibizumab for the treatment of refractory neovascular age-related macular degeneration.
    Marquis LM; Mantel I
    Graefes Arch Clin Exp Ophthalmol; 2020 Aug; 258(8):1591-1596. PubMed ID: 32399582
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Impact of intravitreal ranibizumab, aflibercept and bevacizumab on retinal ganglion cell and nerve fibre layer thickness in Neovascular age-related macular degeneration.
    Abu Dail Y; Seitz B; Sideroudi H; Abdin AD
    Acta Ophthalmol; 2023 May; 101(3):330-341. PubMed ID: 36345883
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Multimodal imaging based biomarkers predictive of early and late response to anti-VEGFs during the first year of treatment for neovascular age-related macular degeneration.
    Tarakcioglu HN; Ozkaya A; Kemer B; Taskapili M
    J Fr Ophtalmol; 2019 Jan; 42(1):22-31. PubMed ID: 30578008
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.